Successful treatment using agalsidase alfa of a patient with Fabry disease who had anaphylaxis after agalsidase beta: A case report

被引：0
|
作者：
Cakmak, Mehmet Erdem [1 ,2 ]
机构：
[1] Basaksehir Cam & Sakura City Hosp, Dept Allergy & Clin Immunol, Istanbul, Turkiye
[2] Basaksehir Cam & Sakura Sehir Hastanesi, Alerji & Immunol Klin, Istanbul, Turkiye
来源：
NORTHERN CLINICS OF ISTANBUL | 2024年 / 11卷 / 01期
关键词：
Agalsidase alfa; agalsidase beta; anaphylaxis; drug allergy; Fabry disease; SUCCESSFUL DESENSITIZATION;
D O I：
10.14744/nci.2022.45656
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Fabry disease is a rare genetic disease caused by a deficiency of alpha-galactosidase A gene (alpha-Gal A). Two intravenous enzymes administered every two weeks, agalsidase alfa and beta can slow disease progression and increase survival if administered early, before organ damage occurs. In this case report, we present a patient with a history of anaphylaxis to agalsidase beta who was successfully treated with agalsidase alfa.
引用
收藏
页码：88 / 90
页数：3
相关论文
共 50 条
  • [1] AGALSIDASE ALFA AND AGALSIDASE BETA FOR TREATMENT OF FABRY DISEASE
    Costa, M. G.
    Santos, M.
    Senna, K.
    VALUE IN HEALTH, 2018, 21 : S439 - S440
  • [2] Successful Desensitization in a Patient with Fabry Disease with Agalsidase Beta Anaphylaxis: A Rare Case Report
    Tuncay, Gulseren
    Bostan, Ozge Can
    Cakmak, Mehmet Erdem
    Kaya, Saltuk Bugra
    Damadoglu, Ebru
    Karakaya, Gul
    Kalyoncu, Ali Fuat
    ASTIM ALLERJI IMMUNOLOJI, 2023, 21 (01): : 68 - 71
  • [3] Successful desensitization in a patient with fabry disease with agalsidase Beta anaphylaxis: A rare case report
    Tuncay, G.
    Can, Bostan O.
    Cakmak, M. E.
    Kaya, S. B.
    Damadoglu, E.
    Karakaya, G.
    Kalyoncu, A. F.
    ALLERGY, 2021, 76 : 261 - 262
  • [4] COST ANALYSIS FOR THE TREATMENT OF FABRY DISEASE WITH AGALSIDASE ALFA AND AGALSIDASE BETA IN COLOMBIA
    Londono, S.
    Pareja, M.
    Becerra, J.
    VALUE IN HEALTH, 2020, 23 : S693 - S693
  • [5] Successful desensitization of a patient with Fabry disease with agalsidase beta (Fabrazyme) anaphylaxis after omalizumab pretreatment
    DuBuske, Ilona
    Schmidlin, Kristin
    Bernstein, Jonathan A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2021, 126 (01) : 96 - 98
  • [6] Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: An international cohort study
    Hollak, Carla E.
    Arends, Maarten
    Wanner, Christoph
    Sirrs, Sandra
    Mehta, Atul
    Elliott, Perry
    Oder, Daniel
    Watkinson, Oliver
    Bichet, Daniel
    Khan, Aneal
    Iwanochko, Mark
    Vaz, Frederic
    van Kuilenburg, Andre B.
    West, Michael L.
    Hughes, Derralynn A.
    Biegstraaten, Marieke
    MOLECULAR GENETICS AND METABOLISM, 2018, 123 (02) : S64 - S65
  • [7] Antibody measurement on switching from agalsidase alfa to agalsidase beta in the treatment of Fabry disease
    Peters, C.
    Burling, K.
    Deegan, P. B.
    ACTA PAEDIATRICA, 2008, 97 : 111 - 112
  • [8] Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?
    Pisani, Antonio
    Riccio, Eleonora
    Sabbatini, Massimo
    GENETICS IN MEDICINE, 2015, 17 (01) : 21 - 23
  • [9] Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study
    Arends, Maarten
    Biegstraaten, Marieke
    Wanner, Christoph
    Sirrs, Sandra
    Mehta, Atul
    Elliott, Perry M.
    Oder, Daniel
    Watkinson, Oliver T.
    Bichet, Daniel G.
    Khan, Aneal
    Iwanochko, Mark
    Vaz, Frederic M.
    van Kuilenburg, Andre B. P.
    West, Michael L.
    Hughes, Derralynn A.
    Hollak, Carla E. M.
    JOURNAL OF MEDICAL GENETICS, 2018, 55 (05) : 351 - 358
  • [10] Enzyme replacement therapy in Fabry disease: Comparison of agalsidase alfa and agalsidase beta
    Mehta, Atul
    Beck, Michael
    Kampmann, Christoph
    Frustaci, Andrea
    Germain, Dominique P.
    Pastores, Gregory M.
    Sunder-Plassmann, Gere
    MOLECULAR GENETICS AND METABOLISM, 2008, 95 (1-2) : 114 - 115
12345